Comparative Pharmacology
Head-to-head clinical analysis: CLOTIC versus LIDEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOTIC versus LIDEX.
CLOTIC vs LIDEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clotrimazole is an imidazole antifungal that inhibits ergosterol synthesis by inhibiting 14α-demethylase (CYP51), leading to disruption of fungal cell membrane integrity and increased permeability.
Glucocorticoid receptor agonist; inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis; suppresses inflammatory cytokines and immune cell migration.
Topical: Apply a thin layer to affected areas 2-4 times daily. Duration limited to 2 weeks; maximum 50 g/week. Intralesional: 0.5-1 mL of 10 mg/mL solution injected into lesion weekly.
Apply a thin film to affected skin areas twice daily. Not for ophthalmic, oral, or intravaginal use.
None Documented
None Documented
Terminal elimination half-life is 3.5 hours (range 2.5-4.5 h) in adults with normal renal function; extends to 6-8 hours in mild-moderate renal impairment.
Terminal elimination half-life: 28-36 hours. Clinical context: Steady-state achieved in ~5-7 days; once-daily dosing maintains therapeutic levels without accumulation in patients with normal renal function.
Renal: 65% as unchanged drug; biliary/fecal: 20% as metabolites; remainder as inactive conjugates.
Renal (primarily as metabolites) ~ 95%; biliary/fecal ~5%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid